-Provide written informed consent prior to initiation of any study procedures, including future use of specimens. -Are able to understand and comply with planned study procedures and be available for all study visits. -Are males or non-pregnant, non-breastfeeding females, 18 to 47 years old, inclusive. -Are in good health, as determined medical history, and targeted physical examination to ensure any existing medical diagnoses or conditions (except those exclusionary) are stable. Note: Stable chronic medical condition - no change in prescription medication, dose, or frequency of medication in the last 3 months (defined as 90 days) and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months (defined as 180 days). Any change that is due to change of health care provider, insurance company etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a violation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a violation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity. Note: Topical, nasal, and inhaled medications (with the exception of steroids as outlined in the Subject Exclusion Criteria (see Section 5.2)), vitamins, and contraceptives are permitted. -Oral temperature is less than 100.4 degrees F -Pulse is 55 to 100 bpm, inclusive. -Systolic blood pressure is 90 to 140 mm Hg, inclusive. -Diastolic blood pressure is 55 to 90 mm Hg, inclusive. -Women of childbearing potential in sexual relationships with men must use an acceptable method of contraception from 30 days prior to pIIV administration until 90 days after last study vaccination. -Note: Not sterilized via tubal ligation, bilateral oophorectomy or hysterectomy and still menstruating or < 1 year of the last menses if menopausal). Includes, but is not limited to, abstinence from intercourse with a male partner, monogamous relationship with a vasectomized partner, male condoms with the use of applied spermicide, intrauterine devices, and licensed hormonal methods, with use of a highly effective method of contraception for a minimum of 30 days prior to study product exposure and agree to practice highly effective contraception for the duration of study product exposure, including 3 months (defined as 90 days) after the last study vaccination. A highly effective method of contraception is defined as one which results in a low failure rate (i.e., less than 1 percent per year) when used consistently and correctly. -Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to study vaccination.